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ABSTRACT: Human cannabinoid type 1 (CB1) G-protein
coupled receptor is a potential therapeutic target for obesity.
The previously predicted and experimentally validated
ensemble of ligand-free conformations of CB1 [Scott, C. E.
et al. Protein Sci. 2013, 22, 101−113; Ahn, K. H. et al. Proteins
2013, 81, 1304−1317] are used here to predict the binding
sites for known CB1-selective inverse agonists including
rimonabant and its seven known derivatives. This binding
pocket, which diﬀers signiﬁcantly from previously published
models, is used to identify 16 novel compounds expected to be
CB1 inverse agonists by exploiting potential new interactions.
We show experimentally that two of these compounds exhibit
inverse agonist properties including inhibition of basal and
agonist-induced G-protein coupling activity, as well as an enhanced level of CB1 cell surface localization. This demonstrates the
utility of using the predicted binding sites for an ensemble of CB1 receptor structures for designing new CB1 inverse agonists.
1. INTRODUCTION
G-protein coupled receptors (GPCRs) are located in the
cellular membrane and act as mediators for cell signaling,
making them promising therapeutic targets. However, drug
design for GPCRs has been challenging due to the paucity of
validated 3D structures. Although these integral membrane
proteins have long been diﬃcult targets for structure
determination eﬀorts, recent methodological developments
now provide structures for ∼33 of the 819 human GPCRs.
Six of these, bovine rhodopsin,1−4 human β2 adrenergic
receptor,5,6 human adenosine A2A receptor,
7−10 human
muscarinic M2 receptor,11 human neurotensin NTS1 recep-
tor,12 and human P2Y12 receptor,13 have been crystallized in an
active or partially active conformation, but only one, human β2
adrenergic receptor, has been cocrystallized with the full
heterotrimeric Gs protein.
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The human cannabinoid 1 (CB1) is a GPCR with high
therapeutic potential as a drug target. This receptor is activated
by Δ9-tetrahydrocannabinol (THC) in marijuana and increases
appetite for AIDS and cancer patients. The CB1-selective
inverse agonist/antagonist rimonabant (also known as
SR141716A)14 is an antiobesity drug that was available in
Europe and was in phase III of US FDA clinical trials but had to
be withdrawn due to severe depressive eﬀects. There is some
indication that these side eﬀects are caused by rimonabant
antagonizing the CB1 receptor activity in brain,15 underscoring
the need for biased inverse agonists for CB1 that are devoid of
these unacceptable side eﬀects. Nonetheless, the intracellular
pathways mediating the beneﬁcial and unwanted eﬀects have
not yet been elucidated.
CB1 has not yet been crystallized; however our previous
studies, using the GEnSeMBLE (GPCR Ensemble of Structures
in Membrane Bilayer Environment) complete conformational
sampling method, predicted the ensemble of ten low energy
CB1 conformations16,17 expected to play a role in binding
various ligands and controlling function. Brieﬂy, GEnSeMBLE
carries out systematic sampling of trillions of seven-helix
bundles by rotating and tilting the transmembrane (TM)
helices starting with templates from previous calculations or X-
ray experiments on other GPCRs. We consider it important to
examine this full conformational space for CB1, because
GPCRs are dynamic and ﬂexible, enabling diﬀerent ligands to
bind to and stabilize quite diﬀerent GPCR conformations. This,
in turn, facilitates coupling to multiple types of intracellular
proteins.18−20
For each of these ten CB1 conformations we used the
hierarchical binding site prediction methods, DarwinDock and
GenDock,21−25 to predict the optimum structures for binding
of rimonabant and seven other ligands. Our predicted ligand−
receptor complexes are in good agreement with published site-
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directed mutagenesis data26−35 and structure−activity relation-
ship (SAR) data.36,37
We then used these predicted binding sites to design and
identify 16 new ligands that we expected might act as inverse
agonists upon binding to the CB1 receptor. Subsequently we
tested ﬁve of these ligands experimentally and found that two
compounds possess inverse agonist properties including
reduced G-protein coupling and changes in cellular localization
of the receptor. This provides new design strategies for
developing more selective and potent CB1 inverse agonists
through computational optimization of chemical functionalities
of the compounds coupled with further pharmacological
characterization.
2. METHODS
We used our GEnSeMBLE method22,38−41 to predict an
ensemble of ten low energy CB1 receptor structures, described
elsewhere.16,17,41 These predictions started with four distinct
templates [bovine rhodopsin,42 turkey ß1 adrenergic receptor,
43
human ß2 adrenergic receptor,
44 and human adenosine A2A
receptor45], optimized the helix shapes within the turkey ß1
adrenergic receptor template, sampled all (12)7 = 35 million
rotations of each of the seven helices independently, followed
by sampling of 13 trillion combinations of helix rotations and
tilts to select by energy the best ten conformations of the seven-
helix bundles. We then docked various ligands, ﬁnding the best
GPCR conformation for each ligand. Previous papers16,17,41
have analyzed thoroughly this ensemble for the wild-type and
several mutant receptors, which were used successfully to
predict (in advance of experiment) mutations that would bias
the ensemble toward the fully inactive, the constitutively active,
or the essentially fully active states.
2.1. Docking of Rimonabant to CB1. To obtain a diverse
set of ligand conformations for docking, we generated a total of
83 ligand conformations for rimonabant. The molecular
structure of rimonabant was constructed with Maestro
software,46 and a conformational search was performed with
MacroModel software,47 which generated 83 conformations of
the ligand. Sytematic and extended torsional sampling options
were used where the selected rotatable bonds are rotated 360°
in 30° increments. Ligand conformations that fall within an
energy window of 10 kcal/mol and an RMSD diversity of 0.5 Å
were saved for subsequent steps. The conformational search
was conducted with the OPLS 2005 force ﬁeld48 and in a
dielectric of 80.37 to match water. Subsequently, we preformed
two rounds of clustering for each ligand; in the ﬁrst round we
clustered ligands with a 2.0 Å diversity followed by another
round of clustering with a 1.0 Å diversity. The Mulliken
populations of each atom were calculated with Jaguar
software49 using Density Functional Theory (DFT) with the
B3LYP functional and the 6-31G** basis set. This led to the
selection of nine ligand conformations. An additional ligand
conformation was constructed from existing coordinates from
the crystallized rimonabant in methanol solvate50 deposited in
the Cambridge Structural Database.51 Each ligand was
minimized using the Surface Generalize Born (SGB) solvation
model52 for 100 steps or to a convergence threshold of 0.2
kcal/mol/Å RMS force with the MPSim program.53 For each of
the ten conformations of rimonabant, we used the DarwinDock
and GenDock21−25 methods to predict the optimum binding
site for each of the ten lowest energy protein structures
predicted by GEnSeMBLE for the CB1 receptor.
2.1.1. DarwinDock. The DarwinDock method aims at
generating a complete set of poses for the binding pocket
while using RMSD clustering of the poses to dramatically
reduce the computational cost. To provide ﬂexibility and space
for the ligand to identify favorable binding sites, we replaced
the seven bulky hydrophobic residues (FILMYVW) with
alanines. The mutated residues are called alanized residues,
and the mutated protein is called alanized protein. For each of
the best 100 ligand poses in the alanized protein, we then
dealanized the mutated residues back to their original
hydrophobic identity and optimized their positions along
with those of other residues in the binding site using
SCREAM.54 This leads to a unique set of optimized residue
side chains for each of the 100 ligand poses. In this process we
did not replace the W5.43 residue with alanine because we
consider this tryptophan to be critical for ligand interaction
based on site-directed mutagenesis data,26 leaving its side chain
in the form predicted by SCREAM for each of the ten protein
conformations.
In the pose generation step of DarwinDock, a ligand pose is
acceptable if it clashed or bumped the receptor residues at six
positions or less. First, we used Dock655 to generate 5,000
ligand poses (without evaluating an energy) and clustered them
into families, where every family member is within a 2.00 Å
RMSD of each other. Then, we added 5,000 more ligand poses
from Dock655 and reclustered. This procedure of adding 5,000
poses and reclustering is repeated until the number of new
families generated is less than 2% of the total number of
families in the preceding iteration. Typically, 45,000 poses were
generated leading to 6000−9000 2.0 Å families. At this point
DarwinDock scores the energies of one representative from
each family, the family head, and selects the 10% of family
heads with the lowest Dreiding energies.56 All members of
these respective families are then scored energetically. From
this list of approximately 5000 poses, we select the lowest 50 by
each of three criteria: lowest hydrophobic energy, lowest polar
energy, and lowest total energy, giving at most 150 poses.
2.1.2. GenDock. GenDock was used to reﬁne the 150
docked ligand−receptor poses generated by DarwinDock. In
the SCREAM step,54 “alanized” residues were replaced with the
original hydrophobic residues but using the optimum side chain
rotamers to avoid any clashes with the ligand and other protein
side chains. Then the entire complex was minimized for 10
steps for each case to remove any bad contacts. Next, the
receptor was neutralized, so that the acidic residues (aspartic
acid and glutamic acid) each gained a proton, and the basic
residues (lysine and arginine) each lost a proton. The resulting
receptor−ligand complexes were minimized for 60 steps using
the Dreiding III FF.56 Then for each of the ten receptor
structures and each of the ten ligand conformations (100
complexes total), we selected the lowest binding energy
structure, including strain and ligand solvation, which we
expected to best represent the binding aﬃnity. The binding
energy with strain and ligand solvation is deﬁned as the energy
diﬀerence between the complex and the sum of the receptor
and ligand energies with ligand strain and ligand solvation
included. The selected complex was minimized with the
Dreiding III FF56 with the LJ vdW term (Dreiding III-LJ FF)
in vacuum for 50 steps or to an RMS force threshold of 0.5
kcal/mol/Å using the MPSim program.53
2.2. Validation of Predicted Binding Sites. 2.2.1. Build-
ing and Docking Rimonabant Derivatives for SAR Studies.
We took the most stable predicted rimonabant-CB1 receptor
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complex shown in Figure 1 and extracted the rimonabant.
Then, we modiﬁed it with Maestro software to look like the
new derivative, calculated the Mulliken charges at the B3LYP
DFT level (with Jaguar software), minimized this conﬁguration
with 100 steps of conjugate gradients (or to a threshold of 0.2
kcal/mol/Å) using the MPSim program, and predicted the
binding site using DarwinDock as described above. However,
instead of docking the new ligands to all ten CB1
conformations, we docked only to the alanized CB1 receptor
conformation wild-type 6 (WT6) because it produced the
lowest energy (most stable) complex with rimonabant shown in
Figure 1. We also docked a single ligand conformation derived
from the docked rimonabant pose. We repeated these steps for
seven derivatives and for the original rimonabant ligand as a
control. For rimonabant, we did not alter the ligand structure
but rather docked the optimized ligand conformation. The ﬁnal
complexes were chosen according to the lowest binding energy
including strain and ligand solvation. For comparison of the
experimental binding aﬃnities with the computational energies,
we used the binding energy, that is, the diﬀerence in energy
between the receptor−ligand complex and the receptor and the
ligand structures calculated separately. The ligand strain and
ligand solvation were ignored since we were comparing
energetics across diﬀerent ligands based on the same
rimonabant conformation.
2.2.2. Free Energy and Binding Aﬃnity Calculations. The
experimental change in free energy upon ligand binding to the
receptor, ΔGbindExp , is obtained from the pKi
57 in eq 1:
Δ = − −G RT ln(10 )bindExp Kp i (1)
The pKi is the experimental binding equilibrium constant of
the inhibitory ligand. Since the pKi describes the strength of the
interaction between the receptor and ligand, we use it to derive
ΔGbindExp . The ΔΔGExp, or the diﬀerence in the change in
experimental free energy upon ligand binding for a given
inverse agonist (ΔGbindExp) with respect to the corresponding
value of rimonabant, is determined by eq 2:
ΔΔ = −G RT K
K
ln
(inverse agonist)
(rimonabant)
i
i
Exp
(2)
This expression was used to compare experimental changes
in binding energy with our predicted changes in binding energy
for the series of ligands.
2.3. Computational Discovery of Novel CB1 Ligands
Using the Predicted Ligand Binding Site To Suggest
New Inverse Agonists. Our predicted rimonabant-CB1
binding site was used to identify new potential CB1 inverse
agonists. The predicted pharmacophore (shown in Figure 1B),
was used in a preliminary search over the 2 million compounds
in PubChem58 for ligands that are similar to rimonabant
according to the Tanimoto coeﬃcient,58,59 an indicator of how
similar two 2D ligands structures are to one another. The
Tanimoto coeﬃcient ranges from 0 to 1, with 0 being no
resemblance between the molecules and 1 being identical
molecules. We wanted ligands that are similar to rimonabant,
but which could exploit nearby underused polar and aromatic
residues in the predicted binding site. For example, K7.32 is
located near rimonabant but does not form a hydrogen bond or
salt bridge with it; thus we searched for ligands similar to
rimonabant, with an appropriately placed functional group to
create the new polar interaction. We also wanted a ligand that is
commercially available but has not been previously tested with
CB1, so that our prediction can be tested easily. Once we had
identiﬁed a ligand (MSC1, described later) from PubChem that
met the above criteria, we performed a search in PubChem to
identify ligands similar to MSC1 (scoring >0.90 on the
Tanimoto coeﬃcient) or that have a 2D structure that is 90%
similar to the new PubChem ligand MSC1 and satisfy speciﬁc
constraints coming from the CB1 binding site. The 16 ligands
found by using PubChem in this protocol are denoted by the
acronym “MSC” followed by a number (MSC1−MSC16).
2.4. CB1 Expression and Membrane Preparation.
HEK293 cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal bovine serum and 3.5%
mg/mL glucose at 37 °C in 5% CO2. One day prior to
transfection, cells were seeded at approximately 1 million cells/
100 mm dishes. The cells were transiently transfected by the
calcium phosphate precipitation method.60 At 24 h post-
transfection, the cells were harvested in phosphate buﬀered
saline (PBS) containing mammalian protease inhibitor cocktail
((4−2-aminoethyl)benzene-sulfonyl ﬂuoride, pepstatin A, E-64,
bestatin, leupeptin, and aprotinin) (Sigma-Aldrich, St. Louis,
MO) and lysed by nitrogen cavitation at 750 psi for 5 min. The
Figure 1. (A) The predicted structures for inverse agonist rimonabant
to WT6, the sixth best energetic conformation of the CB1 receptor.
Rimonabant is anchored to CB1 by hydrogen bonds to W5.43 and
K3.28. Hydrogen bond heteroatom distances are indicated in black.
(B) Our predicted pharmacophore shows that in our GEnSeMBLE-
derived CB1 structure rimonabant forms two hydrogen bonds,
including one with W5.43, and have strong aromatic interactions
with the receptor.
Journal of Chemical Information and Modeling Article
DOI: 10.1021/acs.jcim.5b00581
J. Chem. Inf. Model. 2016, 56, 201−212
203
lysate was spun at 500 g for 10 min at 4 °C, and the
supernatant was subsequently spun at 100,000 g for 45 min at 4
°C. The membrane-containing pellet was resuspended in TME
buﬀer (25 mM Tris-HCl, 5 mM MgCl2, and 1 mM EDTA, pH
7.4) containing 7% w/v sucrose.
2.5. Radioligand Binding Assay. Competition binding
assays were performed as described previously61 to determine
the binding aﬃnity of the test compounds to the receptor.
Brieﬂy, 6 μg of membrane preparation was incubated for 60
min in TME buﬀer containing 0.1% fatty acid-free BSA with a
ﬁxed concentration of tracer [3H]SR141716A (43 Ci/mmol,
PerkinElmer Life Sciences (Boston, MA)) typically at its Kd
which was determined from a saturation binding isotherm. At
least nine concentrations of the unlabeled test compound
(ranging between 100 pM and 32 μM) were used for the
binding assays. Nonspeciﬁc binding was determined in the
presence of unlabeled SR141716A (1 μM). The reaction was
terminated by ﬁltration with a Brandell cell harvester through
Whatman GF/C ﬁlter paper, and the radioactivity was
measured.
2.6. GTPγS Binding Assay. GTPγS binding assays were
performed as described previously.62 Brieﬂy, 6 μg of
membranes was incubated for 60 min at 30 °C in GTPγS
binding assay buﬀer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2,
0.2 mM EGTA, and 100 mM NaCl) with the unlabeled 2-
arachidonoylglycerol (2-AG) (at least nine diﬀerent concen-
trations were used ranging between 100 pM and 1 μM), 0.1 nM
[35S]GTPγS (1250 Ci/mmol; PerkinElmer Life Sciences,
Boston, MA), 10 μM GDP (Sigma, St. Louis, MO), and
0.1% (w/v) BSA in the absence and presence of 10 μM test
compounds. The eﬀect of the compound on inhibiting the level
of basal GTPγS binding was evaluated in the absence of agonist.
Nonspeciﬁc binding was determined with 10 μM unlabeled
GTPγS (Sigma, St. Louis, MO). After rapid ﬁltration through
Whatman GF/C ﬁlters the radioactivity trapped in the ﬁlters
was determined by liquid scintillation counting.
2.7. Experimental Ligand and GTPγS Binding Data
Analysis. Data are presented as the mean ± SE or the mean
with the corresponding 95% conﬁdence limits from at least
three independent experiments. The Ki values of the test
compounds were calculated by nonlinear regression using
Prism 6.0 (Graphpad Software Inc., San Diego, CA).61
2.8. Confocal Microscopy. HEK293 cells expressing the
CB1 receptor C-terminally fused to GFP were seeded onto 35
mm glass-bottomed dishes (MatTek, MA) precoated with poly-
D-lysine. Cells were treated with 10 μM MSC compounds or 1
μM rimonabant for various lengths of time and then washed
three times with PBS, followed by ﬁxation with 4%
paraformaldehyde for 10 min at room temperature. Cells
were mounted in Vectashield mounting medium (Vector
Laboratories, CA) and visualized using a Leica TCS SP2
confocal microscope (Leica Microsystems, Wetzler, Germany).
Images were collected from at least three independently
transfected cell dishes and processed for presentation in ﬁgures
using Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA).
3. RESULTS AND DISCUSSION
3.1. Predicting the Binding Site of the Inverse Agonist
Rimonabant to CB1. The predicted lowest energy pose for
the CB1-rimonabant complex is shown in Figure 1A, and the
corresponding pharmacophore is shown in Figure 1B. We
predict that rimonabant is anchored by hydrogen bonds to
W5.43 and K3.28 [Residues are numbered according to the
Ballesteros−Weinstein scheme.63], and indeed previous site-
directed mutagenesis data indicate that mutations of W5.43 and
K3.28 to alanine have the largest eﬀect in decreasing
experimental binding aﬃnity upon mutation to alanine with
>1000-fold and 17.2-fold, respectively.26,28 The components of
the predicted binding energies for this complex are shown in
Table 1, showing contributions from each residue in the
binding site. The most important residue is W5.43 with a
predicted binding contribution to rimonabant of −9.36 kcal/
mol, consistent with the decrease by a factor of >1000 upon
mutation to alanine.26 Indeed our predicted pharmacophore for
rimonabant (Figure 1B) has the signiﬁcant polar and
hydrophobic contacts with the CB1 receptor expected for a
strongly bonding ligand.
According to the cavity analysis in Table 1, K3.28 has the
third largest binding interaction energy (−5.57 kcal/mol) with
rimonabant due to its hydrogen bond with the amide carbonyl
of the ligand. This interaction is also supported by a
mutagenesis study.28 The same experiments with the
rimonabant derivative VCHSR, an analogue of rimonabant
with hydrocarbons replacing the amide and piperidine groups,
showed that the binding aﬃnity remained unaﬀected upon
mutation of K3.28 to alanine. Our study shows that K3.28
interacts with the polar atoms of the amide group or piperidine
ring, including the carbonyl, which agrees with the mutagenesis
study on this ligand that lacks these polar atoms.28
In our docked pose of rimonabant with the WT receptor, the
F3.36 residue has a signiﬁcant interaction with the ligand,
including a van der Waals component of −3.90 kcal/mol. In
binding assays, the F3.36A mutation decreased the binding
aﬃnity of this inverse agonist by 20-fold,27 or 1.78 kcal/mol, for
the CB1 receptor. Interestingly, the F3.36L mutation decreased
the binding aﬃnity by only 2-fold, indicating the importance of
the bulky hydrophobic residue for receptor−ligand interac-
tion.27
We predicted that M6.55 has the second strongest
interaction (−6.8 kcal/mol) with CB1, which is almost entirely
Table 1. Cavity Analyses for the Predicted Complex of
Rimonabant to WT CB1
residuea no.b VdWc Coulombc H-bondc NonBondc,d
TRPe 5.43 −3.146 −2.085 −4.129 −9.360
MET 6.55 −6.043 −0.756 0 −6.799
LYS 3.28 −0.833 −1.410 −3.322 −5.566
PHE 3.36 −3.841 −0.054 0 −3.896
VAL 3.32 −2.904 −0.363 0 −3.267
THR 5.47 −1.912 −0.048 0 −1.960
LEU 6.51 −2.100 0.193 0 −1.907
TRP 6.48 −1.844 0.008 0 −1.837
THR 3.33 −1.889 0.093 0 −1.797
ILE 2.56 −1.449 0.000 0 −1.449
LEU 7.43 −1.382 0.119 0 −1.263
PHE 7.35 −0.959 −0.174 0 −1.134
SER 3.35 −1.385 0.302 0 −1.083
aOnly residues with energies with contributions stronger than 1.0
kcal/mol are shown. bResidues are numbered according to the
Ballesteros−Weinstein scheme.63 cAll energies are in units of kcal/mol.
dThe nonbonding (NonBond) energy in the far right column is the
sum of the van der Waals (VdW) energy, the electrostatic (Coulomb)
energy, and hydrogen bond (H-bond) energy. eResidues forming
hydrogen bonds are highlighted in bold.
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hydrophobic (Table 1). However, experiments show that
mutating M6.55 to alanine decreases the binding aﬃnity to
CB1 by only 3-fold35 or by 0.65 kcal/mol in energy. One
possible explanation is that the M6.55A mutation alters the
binding site and pose for rimonabant in a way that other
residues become available to compensate for the lost
interaction with methionine. We observed similar cases in our
studies of binding of ligands to CCR5.64
3.2. Analysis of the Conformational Ensemble of CB1
Structures. A very important advantage of the GEnSeMBLE
approach is that we have an ensemble of ten low energy
structures to which rimonabant is allowed to bind. We showed
for the adenosine A3 receptor that neither the selective agonists
nor the selective antagonists prefer the lowest energy
apoprotein structures.24 Also, for CCR5 we showed that the
antagonists all prefer to bind to structures that are not the
lowest energy for the apoprotein.64 Similarly for CB1, the most
favorable binding is with WT6, the sixth best conformation for
the apo-CB1 structure, not with the lowest energy apo-CB1
conformation (WT1) (Table 2). Since the ligands do not
preferentially bind to the lowest energy conformation, these
docking results support the concept that GPCRs are highly
dynamic structures that can sample many conformations,
providing an opportunity for diﬀerent ligands that can
selectively bind to diﬀerent conformations, and perhaps lead
to diﬀerent function. The ten CB1 conformations used in this
study range in backbone RMSD from 0.4−2.1 Å. Of course the
protein conformation may change when complexed with the
ligand.
Surprisingly, the WT6 CB1 structure, to which the inverse
agonist rimonabant preferentially binds, lacks the R3.50 and
D6.30 ionic lock, which is generally believed to be important
for preventing activation. Experimental data have shown that
rimonabant inactivates the CB1 receptor,14,37 while our
calculations ﬁnd that the inverse agonist has the best binding
energies with activated CB1 conformations. Indeed of the top
four rimonabant-CB1 complexes, we ﬁnd that three con-
formations (WT6, WT1, and WT5) do not form an ionic lock
to the conserved R3.50 and D6.30.
On the other hand, several studies have suggested that a
R3.50 to D6.30 salt bridge is not necessary for maintaining the
inactive conformation. For example, Audet and Bouvier65
showed that the R3.50 and D6.30 salt bridge is broken in all but
three of the 36 crystallized GPCR structures bound to
antagonists and inverse agonists analyzed. It should be noted
that many crystallized GPCR structures, such as the human
adenosine A2A receptor, contain an inserted T4 lysozyme for
stabilization, which may impact the conformation of the
cytocellular ends of the helices and thus prevent the formation
of the ionic lock.45
In our previous work with the human CB1 receptor, we
showed that a diﬀerent residue, R2.37, plays an important role
in preventing receptor activation.16,17,41 We found that this
residue forms an “ionic lock” via a salt bridge interaction with
D6.30 to stabilize the inactive conformation. Thus, the
traditional R3.50 and D6.30 salt bridge was not essential.
Indeed our calculations found that the rimonabant inverse
agonist did not prefer to bind to the conformations that
contained this signature contact as shown in Table 2. The
rimonabant-bound CB1 conformation WT6 resembles the
predicted structure of a constitutively active mutant, T3.46A/
R2.37A, which also lacks the R3.50 and D6.30 ionic lock.16,17
The two structures have a Cα-RMSD of 1.2 Å, which is smaller
than most crystal structure resolutions10 suggesting that the
two conformations are very similar. For comparison, the
diﬀerence between the WT receptor conformations WT2
(which contains the R3.50+D6.30 salt bridge) and WT6
(without that salt bridge) is 1.8 Å.
3.3. Analysis of Structure−Activity Relationship (SAR)
with Rimonabant Derivatives. To validate our proposed
binding site, we docked seven known derivatives of rimonabant
(Figure 2A) to the CB1 conformation and plotted the
calculated binding energies against the experimental binding
aﬃnity, pKi, to ﬁnd the correlation between the two data sets
(Figure 3). For each ligand, we found the same binding site as
for rimonabant (Figure 2B). Figure 3A shows a comparison
between the pKi of the inverse agonists from Hurst et al.
36 and
our calculated binding energies. We observe a very high
correlation of 93.4%, indicating good agreement between the
trends observed in experimental binding aﬃnities and our own
calculated binding energies. This strongly supports the selected
binding site.
For the inverse agonists from D’Antona et al.,37,66 we
compared these calculated energies with the ΔGbindExp determined
from eq 1. The ΔGbindExp values are within 1 kcal/mol of each
other since the energies are −9.33 kcal/mol for AM-281, −10.0
kcal/mol for AM-251, and −9.70 kcal/mol for rimonabant.
Similarly, both the calculated cavity and binding energies for
the three ligands are approximately within 1 kcal/mol. The
binding energies are −67.4 to −69.0 kcal/mol, which are very
similar and agree with the experimentally observed negligible
changes in free energy upon binding. This excellent correlation
relies on the predicted energies that are based purely on
enthalpy and do not include entropy. However, the entropy
change upon binding of all the ligands should be similar since
they all have the same number of rotatable bonds.
Figure 3B combines the results from Figure 3A with those
regarding the inverse agonists from D’Antona et al.37 for a
single comparison of our calculated binding energies and the
binding aﬃnities from the two experiments. The respective
ΔΔGExp values from eq 2 are plotted against the calculated
binding energies for all eight ligands, leading to an 89.4%
correlation. The excellent agreement between our predicted
energies and the experimental binding aﬃnity shown in Figure
Table 2. Comparison of Receptor Conformations Selected
by the Inverse Agonist Rimonabant
energy
rank
WT conf no. bound to
rimonabantb
binding energy with strain and
rimonabant solvationa
1 WT6 −59.10
2 WT1 −57.24
3 WT9 −55.44
4 WT5 −54.39
5 WT2 −50.97
6 WT7 −50.12
7 WT4 −50.05
8 WT10 −49.59
9 WT8 −49.35
10 WT3 −48.63
aThe complexes are ranked according to best binding energy with
strain and ligand solvation included. bReceptor conformation numbers
that do not contain the conserved R3.50 and D6.30 salt bridge are in
bold.
Journal of Chemical Information and Modeling Article
DOI: 10.1021/acs.jcim.5b00581
J. Chem. Inf. Model. 2016, 56, 201−212
205
3B provides conﬁdence that our predicted binding site for
rimonabant is reasonable.
3.4. Discovery of Novel CB1-Targeting Inverse
Agonists. With a reliable rimonabant binding pharmacophore
for CB1, which is supported by site-directed mutagenesis and
SAR data, we aimed to design a new, more selective CB1
inverse agonist. After the informed search in PubChem,58
described in the Methods section, we selected Zinc08587042,
which we refer to as MSC1 (Figure 4), a ligand with a 68%
similarity to rimonabant according to the 2D Tanimoto
Figure 2. Rimonabant derivatives used in SAR study. (A) Rimonabant and the seven derivatives used in the SAR study. The portions of the ligand
that are diﬀerent from rimonabant are colored in red. The derivatives in the ﬁrst two rows were used in the Hurst et al., 2006 study,36 and the
derivatives in the third row were used in the D’Antona et al., 2006 studies.37,66 (B) Rimonabant and seven derivatives docked to the CB1 complex.
Rimonabant has carbon atoms colored in cyan. The other derivatives have carbon atoms colored in gray.
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coeﬃcient.67 Rather than relying exclusively on PubChem’s
search algorithm, which looks for molecules based on a 0.90
Tanimoto similarity score with respect to rimonabant, we used
the predicted CB1 binding site and searched for a ligand that
maintained key structural aspects of rimonabant and addition-
ally took advantage of underused residues in the binding site.
For example, we wanted to ﬁnd a ligand having the same amide
and pyrazole functional groups to maintain the hydrogen bonds
with K3.28 and W5.43, respectively. Yet, we wanted to replace
the rimonabant piperidine ring with a phenyl ring and a
substituted polar group to improve the interactions with the
aromatic residues that we found nearby and to gain an
additional hydrogen bond with K7.32, which is within the
rimonabant binding site. Furthermore, we wanted to replace
the methyl group of the pyrazole group with a polar substitute
to form a hydrogen bond with S7.39. MSC1 is attractive
because it contains an acetylphenyl group, which we predicted
would reach into the aromatic pocket of the extracellular end,
and a triazole ring, which would replace a methyl group with a
nitrogen atom. We also wanted a small molecule that was
commercially available and that had not been previously tested
with CB1 in bioactivity assays. MSC1 met all of the above
pretesting criteria.
PubChem also identiﬁed 15 other small molecule ligands that
have a 2D structural similarity Tanimoto score of 0.90 with
MSC1 or have 2D structures that are 90% similar to that of
MSC1 (Figure 5). We docked these 16 ligands to the ensemble
of predicted CB1 structures, found their corresponding binding
energies, and predicted their respective pKi values based on
Figure 3. The predicted binding energies are given in
Supporting Information (SI) Table S1. Of the 16 MSC small
molecules, 14 compounds, MSC1− MSC6, MSC8−MSC11,
and MSC13−MSC16 were commercially available.
3.5. Experimental Binding Aﬃnity Data Suggest
MSC1 and MSC3 Are CB1 Ligand Candidates. From the
16 compounds identiﬁed from the computational analyses, we
chose ﬁve compounds based on the 2D structural similarity,
Tanimoto score, and commercial availability. These are MSC1,
MSC3, MSC5, MSC8, and MSC9. To evaluate experimentally
the binding aﬃnities of the compounds, we performed
competition binding experiments using [3H] rimonabant as a
tracer. MSC1, MSC3, and MSC9 bound the receptor with Ki
values of 502 nM, 495 nM, and 4619 nM, respectively (Table
3). These data indicate that while removal of the chloro group
from the chlorophenyl ring of MSC1 does not impact receptor
binding (MSC1 versus MSC3), the position of the methyl
group in one of the biphenyl rings and the acetyl group in the
amide-linked phenyl ring is critical for receptor binding (MSC3
versus MSC9). MSC5 and MSC8 failed to bind CB1 up to 32
μM (Table 3). Unexpectedly, our experimental Ki values
suggested a weaker aﬃnity than rimonabant compared to the
predictions. This may be due to the limitations of force ﬁelds to
reliably predict relative binding aﬃnities.
3.6. MSC1 and MSC3 Inhibit Both Basal and 2-AG-
Induced G Protein Coupling and Enhanced Cell Surface
Expression of CB1. Since the experimental binding aﬃnities
to the CB1 receptor were higher for MSC1 and MSC3 than for
MSC5, MSC8, and MSC9, we further tested MSC1 and MSC3
using [35S]GTPγS binding assays to evaluate changes in G-
protein coupling. We assessed the eﬀect of the compounds on
the basal and the 2-AG-induced GTPγS binding. We chose 2-
AG, the endogenous eicosanoid CB1 agonist for the assay since
Figure 3. Comparison of experimental binding aﬃnities and
computationally calculated energies between receptor and inverse
agonists. (A) Plot showing the correlation of the experimental binding
aﬃnity, pKi, for the six inverse agonists in Hurst et al.
36 versus our
calculated binding energy (red circles). This leads to R2 = 0.93,
indicating that the error bar for our calculations is ∼2 kcal/mol, while
the range is 18 kcal/mol. (B) Plot showing the correlation of the
ΔΔGexp for seven previously published inverse agonists with respect to
that of rimonabant36,37 versus the calculated binding energy. R2 = 0.89,
indicating that the error bar for our calculations is ∼2 kcal/mol, while
the range is 14 kcal/mol.
Figure 4. Proposed CB1 inverse agonist MSC1 (Zinc08587042).
Structure comparison of rimonabant (top) with MSC1 (bottom).
MSC1 has a 2D structure that is 68% similar to rimonabant. Portions
of MSC1 highlighted in red are diﬀerent from the corresponding
groups in rimonabant.
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it showed binding aﬃnity comparable to MSC1 and MSC3.
Thus, MSC1 and MSC3 can potentially compete with 2-AG.
The addition of 10 μM of MSC1 and MSC3 resulted in
substantial reduction in Emax values with 90 fmol/mg and 81
fmol/mg, respectively, compared with that in the absence of
these MSC compounds (Emax = 126 fmol/mg) (Figure 6A).
These compounds also exhibited small but not statistically
signiﬁcant shifts in EC50 values (785 nM for MSC1, 770 nM for
MSC3, compared to 521 nM for the absence of any MSC
compound). Thus, the extent of G protein coupling (Emax
values) changes, though the amount of agonist needed to
achieve this level of GTPγS binding (EC50 values) does not.
Furthermore, Figure 6B showed that both MSC1 and MSC3
substantially decreased the basal [35S]GTPγS binding (67
fmol/mg) with speciﬁc binding of 50 fmol/mg and 47 fmol/
mg, respectively.
Whereas prolonged agonist treatment can remove receptors
from the cell surface by endocytosis, inverse agonists have been
shown to enhance the cell surface localization, consistent with
receptor inactivation.68,69 CB1 exhibits some constitutive
activity, and the majority of CB1 receptors are localized on
intracellular vesicles even in the absence of agonist.61,70,71 We
tested if the MSC compounds can aﬀect cellular localization of
the receptor using confocal microscopy of cells expressing
GFP-tagged CB1. Similarly to rimonabant treatment, upon
treatment with 10 μM MSC1 or MSC3 the level of cell surface
localization of the receptor was enhanced though the extent for
MSC3 is less than MSC1 (Figure 6C). Collectively, although
MSC1 and MSC3 exhibited somewhat lower potency and
eﬃcacy compared to rimonabant, these data suggest that they
possess inverse agonist properties as evidenced by reduction in
G-protein coupling and enhancement of CB1 cell surface
expression. We took the MSC1-bound CB1 structure and
relaxed it in an explicit lipid bilayer environment using 50 ns of
molecular dynamics (MD) simulations. These MD simulations
are performed under isothermal−isobaric conditions (NPT) at
310 K and 1 atm, using periodic boundary conditions with
Particle-Mesh Ewald summation method for calculating long-
range coulomb interactions. The temperature is controlled
using Langevin dynamics, and the pressure is maintained using
a Langevin-Hoover barostat. These simulations showed that
binding of MSC1 to the CB1 receptor constrains TM helix 6
more through additional intracellular couplings preventing the
G-protein from engaging the receptor, which is consistent with
experimental ﬁndings of MSC1 ligand’s inverse agonism. These
results oﬀer opportunities for developing new CB1 inverse
Figure 5. Proposed CB1-selective inverse agonists based on PubChem58 similarity search with MSC1. PubChem identiﬁed 15 ligands that have 2D
structures similar to MSC1.
Table 3. Experiment Binding Results for Rimonabant and
the MSC Compound Bound to the WT CB1 Receptor
compound Ki
a (nM)
rimonabant 3.4 (2.7−4.2)
MSC1 502 (306−825)
MSC3 496 (211−1164)
MSC5 no detectable binding
MSC8 no detectable binding
MSC9 4619 (528−40380)
aKi values were determined from competition binding assays using
[3H]rimonabant as tracer. Data are the median and corresponding
95% conﬁdence limits of three independent experiments performed in
duplicate.
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agonists through the optimization of chemical functionalities of
the compounds and further pharmacological characterization.
3.7. Comparison of Our Predicted Binding Site to
Previous Predictions. Our predicted rimonabant binding site
in CB1 is diﬀerent from previous computational studies that
used the bovine rhodopsin template to create a CB1 homology
structure for docking rimonabant.26,28,72,73 Supporting In-
formation Figure S1 compares the rimonabant pharmacophore
published by Lange and Kruse74 (Figure S1A) with the
pharmacophore from our current study (Figure S1B). Both
agree that rimonabant (Figure S1A) spans the width of the
binding site with the chlorophenyl rings near TM5 and the
piperidine ring near TM3. However, we predict that
rimonabant (Figure S1B) lies parallel to the z-axis passing
from the extracellular to intracellular side of the membrane,
which is perpendicular to the previous models (Figure S1A).
Although both agree that a hydrogen bond forms between
K3.28 and the amide carbonyl of rimonabant, the earlier models
suggest that K3.28 also participates in a salt bridge with
D6.58,26,28,72 which we do not observe. In addition, the
previous models have the W5.43 residue sandwiched by the
two chlorophenyl groups of rimonabant, leading to strong
aromatic interactions. Furthermore, multiple other aromatic
residues in the binding pocket (F3.25, F3.36, W4.64, Y5.39,
W6.48) were found to participate in stacking with the
ligand,26,72,73 whereas in our predicted binding site, it is
W5.43 that has the biggest impact on binding aﬃnity, from the
hydrogen bond with the pyrazole ring of rimonabant. In our
predicted structure, we ﬁnd that the F3.36 residue is
sandwiched by the chlorophenyl groups rather than W5.43.
In addition, a paper from Shim et al. based its CB1 model on
the human ß2 adrenergic receptor
35 to identify a binding site
similar to the one from Lange and Krause74 but with the ligand
lying perpendicular to our predicted structure, with the
piperidine ring pointing to the TM1−2−7 binding pocket
and the chlorophenyl rings pointing toward TM5, where they
form aromatic stacks with W5.43 and W6.48.
One would expect our predicted rimonabant binding site to
be diﬀerent from the previously published ones since our
predicted receptor structures are quite diﬀerent. Speciﬁcally, we
sample all rotations of all helices about their axes and helix tilt
and sweep angles, a total of nearly 13 trillion receptor
conformations. In contrast, the previous studies used homology
models based on the bovine rhodopsin or human ß2 adrenergic
receptor structure templates, so that no rotations or tilting of
the helices were conducted. These three GPCRs have very
similar global conformations, but we performed considerable
sampling to obtain CB1 receptor conformations that were
signiﬁcantly diﬀerent and more stable than the starting
template.16,17,41 The method we used to identify our ﬁnal
receptor-inverse agonist complex is also diﬀerent. The study
from Shim et al.35 used the selection criterion that one of the
two chlorophenyl rings should be near the TM3−5−6
hydrophobic site, so their ﬁnal pose was chosen based on the
interactions of rimonabant with residues for which there was
site-directed mutagenesis data. However, the structures in our
study were based on the binding energy of the complexes, with
no extra conditions imposed. The previously suggested
rimonabant binding pose most similar to ours came from
another study in which the ligand was docked to a bovine
rhodopsin structure-based homology model.75 This predicted
binding site is similar to the current model, with rimonabant
sitting vertically in the binding pocketthe piperidine ring
points toward the extracellular end and the chlorophenyl rings
point toward the intracellular end. However, it does not lead to
any hydrogen bonds with W5.43 and ﬁnds a hydrogen bond
with Y5.39, that we did not observe.
4. CONCLUSIONS
Since many antiobesity drugs including rimonabant have been
suspended from the market, there remains an enormous unmet
need for compounds that reduce food intake. In an eﬀort to
develop novel inverse agonists for CB1, we predicted the
Figure 6. Eﬀect of MSC1 and MSC3 on the [35S]GTPγS binding to
HEK293 cell membranes expressing the CB1 WT receptor. (A)
Dose−response curves for 2-AG-induced [35S]GTPγS binding in the
absence (●) or presence of 10 μM (■) MSC1 and MSC3. (B)
Inhibition of basal [35S]GTPγS binding by MSC1 and MSC3. The
levels of untransfected cells (no CB1) and rimonabant treated samples
are shown for comparison. Data are presented as speciﬁc binding of
[35S]GTPγS to the membrane. Nonspeciﬁc binding was determined in
the presence of 10 μM unlabeled GTPγS. All data are the mean ± SE
of at least three independent experiments performed in duplicate. (C)
Cellular distribution of the WT receptor upon treatment with MSC
compounds. HEK293 cells expressing the CB1 WT-GFP receptor
were incubated with vehicle alone (0.03% DMSO), MSC1 (10 μM) or
MSC3 (10 μM) for 6 h. Rimonabant-treated (1 μM) cell is shown for
comparison. Scale bar, 10 μm.
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binding sites and energies for rimonabant and structurally
related molecules to our previously predicted and validated
CB1 receptor conformations. Our calculated binding energies
for the compounds are in good agreement with the previously
reported mutagenesis26,28 and SAR data.36,37 Based on the
predicted binding site of these inverse agonists, we identiﬁed 16
new potential CB1 inverse agonists. We tested ﬁve of these
experimentally and found that two of them (MSC1 and MSC3)
antagonized G-protein coupling and enhanced surface local-
ization of the receptor suggesting they are inverse agonists. The
MD simulations of MSC1:CB1 complex in explicit lipid bilayer
environment show that the relaxed receptor exhibits additional
intracellular couplings that will prevent G-protein coupling,
which is consistent with the characterization of MSC1 as an
inverse agonist. Although MSC1 and MSC3 are less potent
than rimonabant, they provide new starting points for
developing new candidates for antiobesity drugs that target
CB1.
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